Key facts
- This page summarizes Eric K. Rowinsky's Form 4 filing for Fortress Biotech, Inc. (FBIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2024, 16:47.
Eric K. Rowinsky - 01 Jan 2024 Form 4 Insider Report for Fortress Biotech, Inc. (FBIO)
- Reporting relationship
- Director
- Issuer ticker
- FBIO
- Reported as of
- 01 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 16:47:48 UTC
- Prior SEC filing
- 28 Jun 2023
- Next SEC filing
- 20 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Samuel Berry, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric K. Rowinsky filed Form 4 for Fortress Biotech, Inc. (FBIO) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 28 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FBIO
transaction
COMMON STOCK, PAR VALUE $0.001
Award
- Transaction value
- $0
- Shares
- +6,666
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 68,797
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
Footnote F2
One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
Footnote F3
Total holdings include 19,998 shares underlying deferred restricted stock units.